Navigation Links
Cadence Pharmaceuticals to Host Analyst and Investor Day
Date:11/28/2012

SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company will host an Analyst and Investor Day for financial analysts on Thursday, December 6, 2012, from 9:00 am to 12:00 pm EST in New York, NY. Members of the Cadence senior management team will provide an update on the OFIRMEV® (acetaminophen) injection launch, as well as the Company's operations and business development plans. In addition, there will be two presentations by outside experts discussing their experience with OFIRMEV.

  • David J. Cziperle, M.D., FACS, Clinical Assistant Professor Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Director Thoracic and Cardiovascular Surgery Silver Cross Hospital
  • John Marshall, PharmD, BCPS, Clinical Coordinator – Critical Care, Beth Israel Deaconess Medical Center
  • Presentations will begin at 9:00 am EST.  For additional information and registration, please e-mail cadence@westwicke.com, or call 858-356-5930.

    A live webcast of the event will be accessible from the Company's website at investors.cadencepharm.com. Please allow extra time prior to the webcast to visit the site and download any streaming media software that may be required to listen to the broadcast. The event will be archived on the Company web site for 90 days.

    About OFIRMEV® (Acetaminophen) Injection
    OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

    Important Safety Information
    Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

    For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

    About Cadence Pharmaceuticals, Inc.
    Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the "Investors" page of www.cadencepharm.com under "Events and Presentations."

    Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc.

     Contact:

    William R. LaRueSVP, CFOCadence Pharmaceuticals, Inc.858-436-1400


    '/>"/>
    SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cadence to Open Finished Medical Device Facility
    2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
    3. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
    4. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
    5. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
    6. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
    7. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
    8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    9. Nobel Prize Winner Bruce Beutler joins Sound Pharmaceuticals
    10. Valeant Pharmaceuticals Announces New Management Appointments
    11. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/17/2017)... 17, 2017  Featuring new and ... the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  Royal ... global leader in health technology,  will ... population health management, acute healthcare informatics ... a highly secure, cloud-based ecosystem. Visitors ...
    (Date:2/16/2017)... EXTON, Pa. , Feb. 16, 2017 ... drugs, biologics, and medical devices, is pleased to announce ... Ph.D., has been selected as a winner of the ... SmartCEO Magazine and recognizes driven executives for ... undeniable work ethic. The awards ceremony and celebration is ...
    (Date:2/16/2017)... 16, 2017 The global preparative and process ... by 2021 from USD 5.49 billion in 2016, at ... basis of type, the preparative and process chromatography market ... 2016, the process chromatography segment is expected to account ... process chromatography. Growth in this segment can primarily be ...
    Breaking Medicine Technology:
    (Date:2/18/2017)... ... 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing ... Ken was impressed with the safety and reliability of the Stannah Stairlift as ... show. This endorsement by Ken Matthews can be heard on News Radio WHP ...
    (Date:2/17/2017)... ... ... Smiles by Seese is a comprehensive family dental practice located ... practice as a skilled and highly credentialed dentist who is qualified to perform a ... all ages with excellence in general, restorative, and cosmetic dentistry . Their services ...
    (Date:2/17/2017)... ... February 17, 2017 , ... ... Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, http://www.fdanews.com/deviceapproval ... asking before selecting an FDA approval pathway? , How should they evaluate ...
    (Date:2/17/2017)... ... February 17, 2017 , ... ... 2017 season , Trinity Health and the U.S. Soccer Foundation announced today that ... in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids ...
    (Date:2/17/2017)... ... , ... Like most hospitals across the nation, Onslow Memorial Hospital is looking ... Readmission Reduction Program (HRRP), the return of a patient to the hospital within 30 ... While many providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital ...
    Breaking Medicine News(10 mins):